Prima Biomed Ltd
ASX:PRR ISIN:AU000000PRR9
Prima Biomed (ASX:PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima's lead product, CVac(tm) has completed Phase IIa clinical development in Ovarian Cancer and is working to a path of US FDA IND approval.
查看其它語言版本
新聞
2011年2月21日澳洲股市報告包括：Prima BioMed Limited (ASX:PRR)將開始可能成為世界首個卵巢癌免疫疫苗的第三階段臨床試驗；Redstone Resources Limited (ASX:RDS)公佈西澳Tollu銅項目的更多高品位銅礦結果；Western Desert Resources Limited (ASX:WDR)報告北領地Roper Bar鐵礦石項目的更多高品位鐵礦石結果；Canyon Resources Limited (ASX:CAY)在布基納法索的加快鑽探作業進展更新。
###
140,310 公司背景瀏覽
- 本頁瀏覽人次: (過去7日: 24) (過去30日: 86) (自發布以來: 11722)
